Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

EASL Recommendations on Treatment of Hepatitis C 2018

Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo et al. · Journal of Hepatology · 2018 · 2.8K citations

Pharmacy, Internal Medicine, Pharmacotherapy +14

EASL Recommendations on Treatment of Hepatitis C 2016

Journal of Hepatology · 2016 · 978 citations

Pharmacy, Internal Medicine, Pharmacotherapy +14

Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

Gary L. Davis, Miriam J. Alter, Hashem B. El‐Serag et al. · Gastroenterology · 2009 · 882 citations · Full text

Education, Geriatric Medicine, Infectious Diseases +10

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

Fred Poordad, Christophe Hézode, Roger Trinh et al. · New England Journal of Medicine · 2014 · 877 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 666 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15